Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20150808023559N21
IRCT20150808023559N21
Recruiting
Phase 1

The Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVID

Ardabil University of Medical Sciences0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Ardabil University of Medical Sciences
Enrollment
60
Status
Recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Definitive diagnosis of Covid19 based on PCR
  • •Blood oxygen saturation less than 90%
  • •No recovery within 48 hours of routine treatment

Exclusion Criteria

  • •History of allergic reactions to blood products injection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2020/04/024706Institute of Liver and Biliary Sciences29
Completed
Phase 3
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2020/06/025803Institute of Liver and Biliary Sciences400
Not yet recruiting
Early Phase 1
Evaluation of Convalescent Plasma Therapy for COVID-19 Patients
IRCT20200503047281N1Yazd University of Medical Sciences40
Completed
Phase 2
Efficacy of Combined Convalescent Plasma Therapy with Oral RNA-dependent RNA Polymerase Inhibitor versus Monoclonal Neutralizing Antibody Therapy among Mild to Moderate COVID-19 in Outpatients: Multicenter, Non-inferiority, Open-label Randomized Controlled TrialMild to moderate COVID-19 (non-severe COVID-19)COVID-19, SARS-CoV-2, favipiravir, sotrovimab, convalescent plasma therapy, monoclonal neutralizing antibody
TCTR20220319002Chulabhorn Royal Academy136
Not yet recruiting
Not Applicable
A Study to find out the effect of blood purification (replacing the liquid part of blood) in improving the survival of children with severe infection and organ failureHealth Condition 1: R652- Severe sepsis
CTRI/2021/07/035316Intramural Research Fund JIPMER